Clinical trials: Birch Pollen Allergy
Hypersensitivity, Allergic Rhinitis
Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis
The purpose of this 2-year study is to assess the sustained clinical efficacy and safety of 300 IR/day of a sublingual solution of birch pollen allergen extract starting 4 months prior to the birch pollen season and continuing…
- Conditions
- Hypersensitivity, Allergic Rhinitis, Allergic Conjunctivitis, Seasonal Allergy
- Trial name
- NCT01731249
- Testing
- Birch pollen allergen extract
- Where
- 11 sites in Czechia, Denmark and 9 more
- Volunteers
- 574 people
- Sponsor
- Stallergenes Greer
Allergic Rhinitis, Conjunctivitis
Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
Primary objective: To assess the efficacy of a single dose of the anti- Bet v 1 monoclonal antibodies (mAb(s ) in the reduction of allergic nasal symptoms during an out-of-season birch allergen environmental exposure unit (EEU)…
- Trial name
- NCT05430919
- Testing
- REGN5713, REGN5714, REGN5715
- Where
- 3 sites in Canada
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Allergic Rhinitis, Conjunctivitis
Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.
- Trial name
- NCT04709575
- Testing
- REGN5713, REGN5714, REGN5715
- Where
- 37 sites in United States, Belgium and 3 more
- Volunteers
- 353 people
- Sponsor
- Regeneron Pharmaceuticals
Hypersensitivity
Vestibular Versus Sublingual Route of AIT Tablets
To evaluate the tolerability of the vestibular administration route of birch pollen, grass pollen, ragweed pollen, and house dust mite (HDM) AIT tablets compared with the sublingual route in adult subjects with allergic…
- Trial name
- NCT05119751
- Testing
- tree 12 SQ-Bet, GRASS 2800 BAU, RAGWEED 12 AMB A 1-U
- Where
- Canada
- Volunteers
- 172 people
- Sponsor
- Clinique Spécialisée en Allergies de la Capitale
Type I Hypersensitivity
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00118625
- Testing
- Tree MATA MPL
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Allergy Therapeutics
Allergic Rhinitis/Rhinoconjunctivitis +-Intermittent Asthma, Sensitization Against Betula Alba (Birch) Pollen
Depigoid Birch 5000 Longterm Study in Adults and Adolescents
Specific immunotherapy for IgE mediated sensitization to birch pollen. Long-term study to assess safety and efficacy of Depigoid(R)Birch 5000 - a modified pollen extract of Betula alba (Birch) - versus placebo.
- Trial name
- NCT01694836
- Testing
- s.c. injection
- Where
- 2 sites in Germany
- Volunteers
- 634 people
- Sponsor
- Leti Pharma GmbH
Birch Pollen Allergy
Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutanous Allergen Exposure
It is an open-label physiological investigation of the allergic skin reactivity to epicutaneous allergen exposition in 20 allergic patients in two different skin conditions.
- Trial name
- NCT02074930
- Testing
- Microporation by P.L.E.A.S.E. Professional / Prick needle
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Birch Pollen Allergy
Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment
Study aiming to evaluate the efficacy of a 2-month pre-seasonal treatment with an AllerT 50 µg or 100 µg maintenance dose administered in previous study AN004T in reducing symptoms of allergic rhinoconjunctivitis during the 2nd…
- Trial name
- NCT02143583
- Where
- 22 sites in Denmark, France and 5 more
- Volunteers
- 196 people
- Sponsor
- Anergis
Allergy
Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients
To compare versus placebo the efficacy and safety of recombinant Bet v1, natural purified Bet v1 and birch pollen licenced extract used for subcutaneous immunotherapy.
- Trial name
- NCT00410930
- Testing
- Subcutaneous immunotherapy - Recombinant birch pollen
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Stallergenes Greer
Allergic Rhinitis Due to Pollen
Nasal Allergen Challenge Test as a Method to Detect Clinical Reactivity Against Birch Pollen
Clinical efficacy and tolerability for allergen specific immunotherapy (AIT) with Itulazax (birch pollen extract tablet) is well established.
- Trial name
- NAC (NCT06085963)
- Testing
- ITULAZAX 12 SQ-Bet, Nacl
- Where
- Sweden
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Birch Pollen Allergy
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis
Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis
- Trial name
- NCT00309062
- Testing
- Recombinant birch pollen
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Rhinitis, Allergic Rhinoconjunctivitis
PURETHAL Birch RUSH Study
This study investigates the safety of two up-dosing regimen. The safety of PURETHAL Birch will be evaluated in a rush regimen (maximum dose reached in 3 injections during 3 weeks) compared to the conventional regimen (maximum…
- Trial name
- NCT01918956
- Testing
- PURETHAL Birch, 20.000 AUM/ml
- Where
- 8 sites in Poland
- Volunteers
- 120 people
- Sponsor
- HAL Allergy
Allergic Rhinitis
Skin Prick Tests With AllerT in Subjects Allergic to Birch Pollen
Assessment of skin reactivity by skin prick tests to synthetic peptides derived from the major birch allergen bet v 1, in subjects allergic to birch pollen.
- Trial name
- NCT01719133
- Testing
- Histamine, AllerT1, AllerT2
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Anergis
Healthy Volunteers, Birch Pollen Allergy
Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants
The primary objective of the study is to evaluate the safety and tolerability of REGN5713-5714-5715 in healthy adult participants.
- Trial name
- NCT03969849
- Testing
- REGN5713-5714-5715
- Where
- 3 sites in Belgium
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Birch Pollen Allergy, Healthy Control Subjects
Effect of the Nasal Provocation on the Breathing Style
The purpose of this study is to find out how the provocation of the nose changes breathing style (specifically, frequency and tidal volume changes)
- Trial name
- NCT02146300
- Testing
- 1. session birch pollen nasal exposure 2. session xylometazoline nasal exposure
- Where
- Finland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Oulu University Hospital
Allergy
A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis
This is a clinical study in children and adolescents (5-17 years) with allergy to pollen from birch (or related trees). It compares the tree SLIT-tablet with placebo in relieving rhinoconjunctivitis symptoms during the birch/tree…
- Trial name
- TreeTop (NCT04878354)
- Testing
- Tree SLIT-tablet
- Where
- 80 sites in Austria, Belgium and 9 more
- Volunteers
- 952 people
- Sponsor
- ALK-Abelló A/S
Allergic Conjunctivitis
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
This study is researching 2 experimental drugs, REGN5713 and REGN5715. The study drugs will be either of these drugs given alone (either REGN5713 or REGN5715) or given together (REGN5713 and REGN5715) to reduce eye allergy signs…
- Trial name
- NCT07309432
- Testing
- REGN5713, REGN5715
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regeneron Pharmaceuticals
Allergy
Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever
The trial is performed to assess the efficacy and safety of SLIT One birch for treatment of birch pollen induced allergy
- Trial name
- NCT00310466
- Testing
- Sublingual immunotherapy
- Where
- Germany
- Volunteers
- 226 people
- Sponsor
- ALK-Abelló A/S
Rhinoconjunctivitis
Open Label Safety Study of a Birch Pollen Allergen Extract
This trial is performed to assess safety of a sublingual birch pollen extract.
- Trial name
- NCT00818181
- Testing
- Biological: AL0206st
- Where
- Germany
- Volunteers
- 73 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Rhinitis, Allergic Rhinoconjunctivitis
SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding
The aim of the study is to determine the optimal effective dose of SUBLIVAC FIX Birch based on reduction of upper airways reactivity after 5 months of treatment with different dosages of SUBLIVAC FIX Birch compared to placebo.
- Trial name
- NCT01639768
- Testing
- SUBLIVAC FIX Birch
- Where
- 20 sites in Czechia, Germany and 1 more
- Volunteers
- 270 people
- Sponsor
- HAL Allergy